Evidence map›Paper›PMID 39291476›Full record

SynthesisJournal of the American Heart Association2024

Surgery Versus Thrombolytic Therapy for the Management of Left-Sided Prosthetic Valve Thrombosis Without Hemodynamic Compromise: A Systematic Review and Meta-Analysis.

Romain Chopard, Charles Vidoni, Matthieu Besutti, Maria Ismail, Fiona Ecarnot, Baptiste Favoulet, Marc Badoz, François Schiele, Andrea Perrotti, Nicolas Meneveau

Abstract readComparative StudyMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Romain ChopardDepartment of Cardiology University Hospital Besançon France.ORCID 0000-0002-8358-515X
Charles VidoniDepartment of Cardiology University Hospital Besançon France.ORCID 0009-0003-4695-3077
Matthieu BesuttiDepartment of Cardiology University Hospital Besançon France.
Maria IsmailDepartment of Thoracic and Cardio-Vascular Surgery University Hospital Besançon France.ORCID 0009-0008-3729-2007
Fiona EcarnotDepartment of Cardiology University Hospital Besançon France.ORCID 0000-0002-4224-9731
Baptiste FavouletDepartment of Cardiology University Hospital Besançon France.
Marc BadozDepartment of Cardiology University Hospital Besançon France.
François SchieleDepartment of Cardiology University Hospital Besançon France.ORCID 0000-0003-4974-6551
Andrea PerrottiDepartment of Thoracic and Cardio-Vascular Surgery University Hospital Besançon France.
Nicolas MeneveauDepartment of Cardiology University Hospital Besançon France.ORCID 0000-0002-1017-0463

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe optimal strategy in prosthetic heart valve thrombosis (PVT) remains controversial, with no randomized trials and conflicting observational data. We performed a systematic review and meta-analysis of evidence comparing systemic thrombolysis and cardiac surgery in PVT. METHODS AND

resultsWe searched PubMed, the Cochrane Library, and Embase for studies on treatment strategies in patients with left-sided PVT since 2000. The primary outcome was death, and the secondary outcomes were major bleeding and thromboembolism during follow-up (International Prospective Register of Systematic Reviews No. CRD42022384092). We identified 2298 studies, of which 16 were included, comprising 1389 patients with PVT (mean age, 50.4±9.3 years; 60.0% women). Among them, 67.2% were New York Heart Association stage III/IV at admission. Overall, 48.1% were treated with systemic thrombolysis and 51.9% with cardiac surgery. The mortality rate was 10.8% in the thrombolysis group and 15.3% in the surgery group. The pooled risk difference for death with systemic thrombolysis was 1.13 (exact CI, 0.74-1.79;

conclusionsThere is evidence to suggest that thrombolysis might be the preferred option for the management of PVT without cardiogenic shock, pending future randomized controlled trials or larger observational studies.

Indexed as

Heart Valve ProsthesisThrombolytic TherapyThrombosisCardiac Surgical ProceduresFemaleFibrinolytic AgentsHeart Valve Prosthesis ImplantationHemodynamicsHumansMaleTreatment OutcomeFibrinolytic Agentsmeta‐analysisprosthetic valve thrombosissurgerythrombolysis

Identifiers

PMID39291476
PMCPMC11681445

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.